Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
  • Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
  • Braftovi® (encorafinib) + Mektovi® (binimetinib)​: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
  • Duchenne Muscular Dystrophy Gene Therapy
  • fidanacogene elaparvovec (Coagulation Factor IX Gene Therapy): Hemophilia
  • giroctocogene fitelparvovec: Hemophilia Gene Therapy
  • Ibrance® (palbociclib): High Risk Early Breast Cancer, Early Breast Cancer in Adjuvant Setting, HER2+ Breast Cancer
  • Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
  • Prophylactic Vaccine: Clostridioides difficile Infection
  • Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata, Vitiligo
  • Talzenna® (talazoparib): Prostate Cancer
  • Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
  • Xeljanz® (tofacitinib): Ankylosing Spondylitis
  • Xtandi® (enzalutamide): Metastatic Hormone Sensitive Prostate Cancer, Non-Metastatic High Risk Hormone Sensitive Prostate Cancer

Pipeline Snapshot as of April 28, 2020

  • Discovery Projects
  • Phase 1
    27
  • Phase 2
    37
  • Phase 3
    21
  • Registration
    6
  • Total91
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
PF-06801591 + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder Cancer (Biologic) Phase 3 New Molecular Entity Biologic
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer Phase 3 Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High Risk Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Merkel Cell Carcinoma (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/CMP-001 for Head and Neck Cancer Phase 2 Product Enhancement Biologic
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
BRAF-mutant Metastatic Melanoma (ORPHAN - U.S.) Phase 2 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
1st Line BRAF-mutant Colorectal Cancer Phase 2 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
1st Line BRAF-mutant Non-Small Cell Lung Cancer Phase 2 Product Enhancement Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Myelodysplastic Syndrome Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer Phase 2 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Cancer (Biologic) Phase 1 Product Enhancement Biologic
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
CD137 Agonist
Combo w/Kite Pharma'sYescarta (axicabtagene ciloleucel)forCancer Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Cancer (Biologic) Phase 1 New Molecular Entity Biologic